

- **Name:** Sung Hee Lim
 - **Current Position & Affiliation:** Division of Oncology-Hematology, Department of Internal medicine, Soonchunhyang University Bucheon Hospital
 - **Country:** Republic of Korea
-

• **Educational Background:**

- March 2015 ~ February 2020: Doctor of Medicine, majored in molecular oncology at Sungkyunkwan University School of Medicine, Seoul, Korea
- March 2013 ~ February 2015: Master of Medicine, majored in internal medicine at Sungkyunkwan University School of Medicine, Seoul, Korea
- March 2003 ~ February 2009: Bachelor of Medicine, majored in medicine at Yonsei University, College of Medicine, Seoul, Korea

• **Professional Experience:**

- Mar 2017 – Current: *Assistant Professor*, Division of Oncology-Hematology, Department of Internal medicine, Soonchunhyang University Bucheon Hospital, Bucheon, Korea
- Mar 2016 – Feb 2017: *Clinical Fellowship*, Division of Hematology-Oncology, Department of Medicine, Dongtan Sacred Heart Hospital, Hallym University of College of Medicine, Hwaseong, Korea
- Mar 2014 – Feb 2016: *Clinical Fellowship*, Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
- Mar 2010 – Feb 2014: *Residency in Internal Medicine*, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
- Mar 2009 – Feb 2010: *Internship*, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea

• **Professional Organizations:**

- Korean Society of Medical Oncology
- Korean Cancer Study Group
- The Korean Cancer Association
- American Society of Clinical Oncology

• **Main Scientific Publications:**

1. Serum Antibody Response Comparison and Adverse Reaction Analysis in Healthcare Workers Vaccinated with the BNT162b2 or ChAdOx1 COVID-19 Vaccine Vaccines. *Vaccines* (Basel). 2021 Nov 24;9(12):1379. doi: 10.3390/vaccines9121379.

2. Osimertinib for Patients With Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Multicenter, Open-Label, Phase II Trial (KCSG-LU15-09). *J Clin Oncol*. 2020 Feb 10;38(5):488-495.
3. Gemcitabine and Erlotinib with or without Oxaliplatin in Previously Untreated Advanced Pancreatic Cancer: A Randomized Phase II Trial. *Yonsei Med J*. 2021 Aug;62(8):671-678
4. Systematic Evaluation of Gastric Tumor Cell Index and Two-Drug Combination Therapy via 3-Dimensional High-Throughput Drug Screening. *Front Oncol*. 2019 Nov 29;9:1327
5. Induction chemotherapy followed by concurrent chemoradiotherapy versus CCRT for locally advanced hypopharynx and base of tongue cancer. *Korean J Intern Med*. 2021 Mar;36(Suppl 1):S217-S224.
6. Beyond first-line non-anthracycline-based chemotherapy for extranodal NK/T-cell lymphoma: clinical outcome and current perspectives on salvage therapy for patients after first relapse and progression of disease. *Ann Oncol*. 2017 Sep 1;28(9):2199-2205
7. TET2 Mutation and High miR-22 Expression as Biomarkers to Predict Clinical Outcome in Myelodysplastic Syndrome Patients Treated with Hypomethylating Therapy. *Curr Issues Mol Biol*. 2021 Aug 5;43(2):917-931
8. Liposomal irinotecan plus fluorouracil/leucovorin versus FOLFIRINOX as the second-line chemotherapy for patients with metastatic pancreatic cancer: a multicenter retrospective study of the Korean Cancer Study Group (KCSG). *ESMO Open*. 2021 Apr;6(2):100049.